Restoration of ampicillin susceptibility in drug-resistantenterococcus faecalisvia synergistic therapy with

Qingqing Li1, Mingzhi Huang2, Peng Wang1

  • 1Department of Stomatology, Gansu Provincial Hospital, Lanzhou 730000, People's Republic of China.

Insights

A novel combination therapy using methimazole-melamine co-functionalized gold nanoparticles (Mel-MMI@Au NPs) with ampicillin shows synergistic effects against multidrug-resistant Enterococcus faecalis. This approach enhances antibiotic efficacy and delays resistance evolution.

Area of Science:

  • Nanotechnology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Enterococcus faecalis is a major cause of nosocomial infections, exhibiting significant multidrug resistance.
  • Current therapies combining ampicillin with other antibiotics face challenges like toxicity and promoting resistance.

Purpose of the Study:

  • To develop a novel combination strategy against multidrug-resistant E. faecalis.
  • To evaluate the efficacy of methimazole-melamine co-functionalized gold nanoparticles (Mel-MMI@Au NPs) combined with ampicillin.

Main Methods:

  • Synthesis and characterization of Mel-MMI@Au NPs.
  • Assessment of antibacterial activity and stability of Mel-MMI@Au NPs compared to single-ligand nanoparticles.
  • Evaluation of the synergistic effect of Mel-MMI@Au NPs and ampicillin using MIC and FICI.

Main Results:

  • Mel-MMI@Au NPs demonstrated superior stability and antibacterial activity.
  • The combination therapy significantly reduced ampicillin's minimum inhibitory concentration (MIC) by eightfold.
  • A fractional inhibitory concentration index (FICI) of 0.375 confirmed robust synergistic antibacterial activity.

Conclusions:

  • The dual-modified gold nanoparticle-antibiotic strategy achieves low-dose synergistic bactericidal activity.
  • This approach effectively overcomes limitations of single antibiotics and delays resistance evolution.
  • Mel-MMI@Au NPs combined with ampicillin represent a promising therapeutic strategy for multidrug-resistant E. faecalis infections.